Which has the lower trailing P/E, ARVN or PBYI?

PBYI has the lower trailing P/E: ARVN trades at 46.06 and PBYI at 18.47. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ARVN or PBYI?

Over the past five years, ARVN grew revenue faster — ARVN at a 72.38% CAGR versus PBYI at 0.29%.

Is ARVN or PBYI more profitable?

PBYI runs the higher net margin — ARVN at 2.94% versus PBYI at 11.55%.

How have ARVN and PBYI total returns compared?

Over the past 5 years, ARVN delivered -38.16% and PBYI delivered 9.26% annualized total return. Past performance doesn't predict future results.

Arvinas, Inc. (ARVN) vs Puma Biotechnology, Inc. (PBYI)

A side-by-side comparison of Arvinas, Inc. and Puma Biotechnology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ARVN

Arvinas, Inc.

$476M

$7.37HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT

PBYI

Puma Biotechnology, Inc.

$485M

$9.54HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT

Total return — ARVN vs PBYI

growth of $100 · dividends reinvested · last 8y

ARVN -53.5% (-9.1%/yr)PBYI -79.3% (-17.9%/yr)ARVN compounded faster over this window

ARVN PBYI

ARVN vs PBYI: by the numbers

•PBYI is the larger company ($485M vs $476M market cap).
•PBYI trades at the lower trailing earnings multiple (18.47 vs 46.06 P/E), one valuation lens rather than an overall verdict.
•PBYI converts more revenue to profit (11.55% vs 2.94% net margin).
•ARVN grew revenue faster over the past five years (72.38% vs 0.29% CAGR).

Metrics side by side

Valuation

Metric	ARVN	PBYI
P/E ratio	46.06	18.47
Forward P/E	N/A	25.09
P/S ratio	1.50	2.10
P/B ratio	0.85	3.50
EV / EBITDA	N/A	10.45
FCF yield	N/A	8.47%

Profitability

Metric	ARVN	PBYI
Gross margin	96.43%	74.83%
Operating margin	-43.75%	13.16%
Net margin	2.94%	11.55%
ROE	1.65%	19.28%
ROIC	-2.19%	18.26%

Growth (annualized)

Metric	ARVN	PBYI
Revenue CAGR (5Y)	72.38%	0.29%
FCF CAGR (5Y)	N/A	90.51%
Total return CAGR (5Y)	-38.16%	9.26%

Frequently asked

Which has the lower trailing P/E, ARVN or PBYI?: PBYI has the lower trailing P/E: ARVN trades at 46.06 and PBYI at 18.47. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ARVN or PBYI?: Over the past five years, ARVN grew revenue faster — ARVN at a 72.38% CAGR versus PBYI at 0.29%.
Is ARVN or PBYI more profitable?: PBYI runs the higher net margin — ARVN at 2.94% versus PBYI at 11.55%.
How have ARVN and PBYI total returns compared?: Over the past 5 years, ARVN delivered -38.16% and PBYI delivered 9.26% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ARVN analysis Full PBYI analysis Interactive comparison tool

Dig into the metrics

Arvinas P/E ratio Puma Biotechnology P/E ratio Arvinas ROE Puma Biotechnology ROE Arvinas operating margin Puma Biotechnology operating margin Arvinas revenue growth Puma Biotechnology revenue growth Arvinas free cash flow Puma Biotechnology free cash flow

Arvinas & Puma Biotechnology appear in these rankings

Fastest Revenue Growth Stocks Highest ROIC Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.